Kakafoni Georgia, Zvintzou Evangelia, Kyroglou Smaro, Giannatou Katerina, Mparnia Victoria, Vareltzis Patroklos, Kypreos Kyriakos E
Pharmacology Laboratory, Department of Medicine, University of Patras, 26500 Rio Achaia, Greece.
Laboratory of Food and Agricultural Industries Technologies, Chemical Engineering Department, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Nutrients. 2024 Dec 28;17(1):76. doi: 10.3390/nu17010076.
BACKGROUND/OBJECTIVES: Lavender has been utilized for its medicinal properties since ancient times, with numerous health benefits reported. This study aimed to valorize solid waste from lavender essential oil production by developing a novel lavender extract from solid lavender residues. The extract's preclinical safety and efficacy were evaluated with emphasis on plasma lipid and lipoprotein metabolism, glucose tolerance, and adipose tissue metabolic activity.
Male C57BL/6 mice were divided into four groups of five mice each and fed for 30 days with lavender extract encapsulated in 10% maltodextrin, mixed with a standard chow diet. The first group (Lav 1×) received 21.1 mg/kg/day, the second group (Lav 10×) received 211 mg/kg/day, and the third group (Lav 100×) received 2110 mg/kg/day. A placebo group consumed the standard diet without lavender extract. Key outcomes included plasma lipid and lipoprotein profiles, transaminase levels, HDL antioxidant and anti-inflammatory potential, glucose tolerance, and mitochondrial activity in white (WAT) and brown (BAT) adipose tissues.
The novel lavender extract induced dose-dependent improvements in lipid and lipoprotein metabolism, glucose tolerance, and adipose tissue activity. The 2110 mg/kg dose (100×) demonstrated the most significant beneficial effects, although it was associated with a slight elevation in hepatic transaminase levels, indicating potential mild hepatic stress. Overall, the novel lavender extract exhibits promising health benefits with no major safety concerns at the tested doses, supporting its potential for therapeutic applications.
背景/目的：薰衣草自古以来就因其药用特性而被使用，有众多健康益处的报道。本研究旨在通过从薰衣草固体残渣中开发一种新型薰衣草提取物，来提高薰衣草精油生产过程中固体废弃物的价值。重点针对血浆脂质和脂蛋白代谢、葡萄糖耐量以及脂肪组织代谢活性，对该提取物的临床前安全性和功效进行了评估。
将雄性C57BL/6小鼠分为四组，每组五只，用包裹在10%麦芽糊精中的薰衣草提取物与标准饲料混合喂养30天。第一组（Lav 1×）接受21.1毫克/千克/天的剂量，第二组（Lav 10×）接受211毫克/千克/天的剂量，第三组（Lav 100×）接受2110毫克/千克/天的剂量。一个安慰剂组食用不含薰衣草提取物的标准饮食。关键结果包括血浆脂质和脂蛋白谱、转氨酶水平、高密度脂蛋白的抗氧化和抗炎潜力、葡萄糖耐量以及白色（WAT）和棕色（BAT）脂肪组织中的线粒体活性。
这种新型薰衣草提取物在脂质和脂蛋白代谢、葡萄糖耐量以及脂肪组织活性方面呈现出剂量依赖性的改善。2110毫克/千克的剂量（100×）显示出最显著的有益效果，尽管它与肝转氨酶水平略有升高有关，表明可能存在轻度肝应激。总体而言，这种新型薰衣草提取物在测试剂量下显示出有前景的健康益处，且无重大安全问题，支持其在治疗应用方面的潜力。
